Literature DB >> 8989229

C cell hyperplasia/neoplasia.

V A LiVolsi.   

Abstract

Entities:  

Mesh：

Year:  1997        PMID： 8989229     DOI： 10.1210/jcem.82.1.3707

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  19 in total

1.  Absence of RET gene point mutations in sporadic thyroid C-cell hyperplasia.

Authors:  Enrico Saggiorato; Ida Rapa; Francesca Garino; Gianni Bussolati; Fabio Orlandi; Mauro Papotti; Marco Volante
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

2.  Medullary thyroid carcinoma: a 25-year perspective.

Authors:  Xavier Matias-Guiu; Ronald De Lellis
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

3.  Video assisted prophylactic thyroidectomy and central compartment nodes clearance in two RET gene mutation adult carriers.

Authors:  P Miccoli; R Elisei; P Berti; G Materazzi; L Agate; M G Castagna; B Cosci; P Faviana; C Ugolini; A Pinchera
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

Review 4.  Calcitonin as a biomarker of C cell disease: recent achievements and current challenges.

Authors:  Giuseppe Costante; Domenico Meringolo
Journal:  Endocrine       Date:  2020-01-10       Impact factor: 3.633

5.  Isthmus-preserving total bilobectomy: an adequate operation for C-cell hyperplasia.

Authors:  Robert Arnulf Wahl; Christian Vorländer; Susanne Kriener; Johanna Pedall; Martin Spitza; Martin-Leo Hansmann
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

Review 6.  Update multiple endocrine neoplasia type 2.

Authors:  Friedhelm Raue; Karin Frank-Raue
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

Review 7.  Sporadic and familial medullary thyroid carcinoma: state of the art.

Authors:  Tricia A Moo-Young; Amber L Traugott; Jeffrey F Moley
Journal:  Surg Clin North Am       Date:  2009-10       Impact factor: 2.741

Review 8.  Thyroid safety in patients treated with liraglutide.

Authors:  M Gallo
Journal:  J Endocrinol Invest       Date:  2013-02       Impact factor: 4.256

9.  Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease--a consensus statement of the European Society of Endocrine Surgeons (ESES).

Authors:  Bruno Niederle; Frédéric Sebag; Michael Brauckhoff
Journal:  Langenbecks Arch Surg       Date:  2013-12-03       Impact factor: 3.445

10.  Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.

Authors:  Daniel J Drucker; Steven I Sherman; Fred S Gorelick; Richard M Bergenstal; Robert S Sherwin; John B Buse
Journal:  Diabetes Care       Date:  2010-02       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.